Column Group updates Tenaya Therapeutics ownership
Tenaya Therapeutics’ major shareholder group, The Column Group affiliates, has updated its ownership and recent trading activity in the company’s common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tenaya Therapeutics’ major shareholder group, The Column Group affiliates, has updated its ownership and recent trading activity in the company’s common stock. Several Column Group funds now report no beneficial ownership, while TCG Opportunity III LP and related entities report beneficial ownership of 49,313,559 shares, representing 23.1% of the common stock based on 213,744,535 shares outstanding as of December 15, 2025.
The filing details a series of open-market sales in February 2026 by TCG III LP and TCG III-A LP. On February 20, 2026, they sold 245,965 and 277,769 shares, respectively, at a weighted-average price of $0.6149 per share. On February 23, they sold 143,709 and 162,291 shares at $0.5972 per share, and on February 24, they sold 309,228 and 349,212 shares at $0.6153 per share. On February 25, 2026, TCG III LP sold 1,649,281 shares and TCG III-A LP sold 1,862,545 shares at a weighted-average price of $0.5624 per share.
The filing notes warrants to purchase 53,571,426 additional shares of common stock held by TCG Opportunity III LP that are not exercisable within 60 days because of Beneficial Ownership Limitations. Managing partners Tim Kutzkey and Peter Svennilson are included as reporting persons and may be deemed to share voting, investment and dispositive power over the reported shares through the Column Group structure.
Insights
Large VC holder discloses sizeable stake and recent stock sales.
The Column Group entities report a reshaped ownership profile in Tenaya Therapeutics. Several funds now show zero beneficial ownership, while the TCG Opportunity III structure reports 49,313,559 shares, or 23.1% of common stock, based on 213,744,535 shares outstanding as of December 15, 2025.
Item 3 lists multiple open-market sales in late February 2026 by TCG III LP and TCG III-A LP at weighted-average prices between $0.5624 and $0.6153 per share, generating individual day sale proceeds up to approximately $1.05 million per entity. These are transactions by shareholders, not capital raises for the company.
The filing also highlights warrants to purchase 53,571,426 additional shares that are currently blocked by Beneficial Ownership Limitations, and clarifies that ultimate control sits with TCG Opportunity III GP LLC and its managing members, Tim Kutzkey and Peter Svennilson. Future changes in this group’s stake would likely appear in subsequent beneficial ownership amendments.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much of Tenaya Therapeutics (TNYA) does The Column Group currently report owning?
Do any Column Group entities now report zero beneficial ownership of Tenaya Therapeutics (TNYA)?
Who ultimately controls the Column Group’s reported Tenaya Therapeutics (TNYA) stake?
Why were Tim Kutzkey and Peter Svennilson added as reporting persons for Tenaya Therapeutics (TNYA)?
AI-generated analysis. How Rhea-AI works. Not financial advice.